Ana Laus to Protein Kinase Inhibitors
This is a "connection" page, showing publications Ana Laus has written about Protein Kinase Inhibitors.
Connection Strength
0.199
-
Leal LF, Laus AC, Cavagna R, de Paula FE, de Oliveira MA, Ribeiro DM, Hassan FM, Miziara JE, da Silva ECA, da Silva VD, De Marchi P, Reis RM. EGF+61 A>G polymorphism does not predict response to first-generation EGFR tyrosine kinase inhibitors in lung cancer patients. Thorac Cancer. 2020 10; 11(10):2987-2992.
Score: 0.155
-
da Silva-Oliveira RJ, Gomes INF, da Silva LS, Lengert AVH, Laus AC, Melendez ME, Munari CC, Cury FP, Longato GB, Reis RM. Efficacy of Combined Use of Everolimus and Second-Generation Pan-EGRF Inhibitors in KRAS Mutant Non-Small Cell Lung Cancer Cell Lines. Int J Mol Sci. 2022 Jul 14; 23(14).
Score: 0.044